Skip to main content
Log in

Pharmacokinetics of tolfenamic acid: Disposition in bile, blood and urine after intravenous administration to man

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

To study its pharmacokinetics and especially its biliary excretion, 14C-tolfenamic acid 9.84 µCi/100 mg was infused i.v. in 8 patients with a T-tube inserted in the common bile duct at choledocholithotomy 7–10 days prior to the study. Bile was collected in fractions by continuous suction over a 24 h period. Blood samples were taken and urine collected up to 48 h after the dose. Tolfenamic acid and its metabolites were separated by TLC and were quantitated by liquid scintillation counting. The pharmacokinetics of tolfenamic acid could be described by a two compartment open model with V1 of 3.67±0.68 l and Vss of 8.0±1.0 l. The total plasma clearance of tolfenamic acid averaged 106±8 ml/min and t1/2β was 1.38±0.32 h. A three compartment open model was required to describe the kinetics of total 14C. The plasma clearance of total 14C was 15.4±3.9 ml/min and its terminal half life averaged 19.0±4.1 h. The long half-life was caused by the slow elimination of tolfenamic acid metabolites. Four metabolites were measured in plasma and bile. The principal metabolites in bile were glucuronide/sulphate conjugates of hydroxylated derivatives of tolfenamic acid. The recovery of tolfenamic acid in bile was 1.1±0.3% of the dose, whereas the recovery of total 14C was 18.6±4.9%. The biliary clearances of tolfenamic acid and total 14C were 1.2±0.3 and 5.0±2.1 ml/min, respectively. Thus, biliary excretion plays a considerable part in the pharmacokinetics of tolfenamic acid.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pentikäinen PJ, Neuvonen PJ, Backman C (1981) Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol 19: 359–365

    Google Scholar 

  2. Hucker HB, Zacchei AG, Cox SV, Brodie DA, Cantwell NHR (1966) Studies on the absorption, distribution and excretion of indomethacin in various species. J Pharmacol Exp Ther 153: 237–249

    Google Scholar 

  3. Pentikäinen PJ, Penttilä A, Neuvonen PJ, Khalifah RG, Hignite CE (1982) Human metabolism of tolfenamic acid. I. Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites. Eur J Drug Metabol Pharmacokinet 7: 259–267

    Google Scholar 

  4. Khalifah RG, Hignite CE, Pentikäinen PJ, Penttilä A, Neuvonen PJ (1982) Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates. Eur J Drug Metabol Pharmacokinet 7: 269–276

    Google Scholar 

  5. Riegelman S, Loo JCK, Rowland M (1968) Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci 57: 117–123

    Google Scholar 

  6. Loo TL, Tanner BB, Housholder GE, Shepard BJ (1968) Some pharmacokinetic aspects of 5-(dimethyltriazeno)-imidazole-4-carboxamide in the dog. J Pharm Sci 57: 2126–2131

    Google Scholar 

  7. Brown RD, Manno JE (1978) ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 67: 1687–1691

    Google Scholar 

  8. Loo JCK, Riegelman S (1970) Assessment of pharmacokinetic constants from postinfusion blood curves obtained after i.v. infusion. J Pharm Sci 59: 53–55

    Google Scholar 

  9. Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York

    Google Scholar 

  10. Glazko AJ (1967) Pharmacology of the fenamates. III. Metabolic disposition. Ann Phys Med 9: 23–36

    Google Scholar 

  11. Aarbakke J, Bakke OM, Milde EJ, Davies DS (1977) Disposition and oxidative metabolism of phenylbutazone in man. Eur J Clin Pharmacol 11: 359–366

    Google Scholar 

  12. Duggan DE, Hooke KF, Noll RM, Kwan KC (1975) Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 25: 1749–1754

    Google Scholar 

  13. Kwan KC, Breault GO, Umbenhauer ER, McMahon FG, Duggan DE (1975) Kinetics of indomethacin absorption, elimination and enterohepatic circulation in man. J Pharm Biopharm 4: 255–280

    Google Scholar 

  14. Rollins DE, Klaassen CD (1979) Biliary excretion of drugs in man. Clin Pharmacokinet 4: 368–379

    Google Scholar 

  15. Pedersen SB, Alhede B, Buchardt O, Moller J, Bock K (1981) Tolfenamic acid. Detection and structure of urinary metabolites. Arzneimittelforsch Drug Res 31: 1944–1948

    Google Scholar 

  16. Thornell E, Jansson R, Kral JG, Svanvik J (1979) Inhibition of prostaglandin synthesis as a treatment for biliary pain. Lancet 1: 584

    Google Scholar 

  17. Thornell E, Jansson R, Svanvik J (1981) Indomethacin intravenously — A new way for effective relief of biliary pain: a double-blind study in man. Surgery 90: 468–472

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pentikäinen, P.J., Tokola, O., Alhava, E. et al. Pharmacokinetics of tolfenamic acid: Disposition in bile, blood and urine after intravenous administration to man. Eur J Clin Pharmacol 27, 349–354 (1984). https://doi.org/10.1007/BF00542174

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00542174

Key words

Navigation